Effect of dietary omega-3 fatty acids on high-density lipoprotein apolipoprotein AI kinetics in type II diabetes mellitus
|
|
- Olivia Lyons
- 6 years ago
- Views:
Transcription
1 Atherosclerosis 157 (2001) Effect of dietary omega-3 fatty acids on high-density lipoprotein apolipoprotein AI kinetics in type II diabetes mellitus R. Frénais a, K. Ouguerram a, C. Maugeais a, P. Mahot b, B. Charbonnel b, T. Magot a, M. Krempf a,b, * a Centre de Recherche en Nutrition Humaine, Groupe Métabolisme, INSERM U539, Hôtel Dieu, Nantes, France b Clinique d Endocrinologie, Maladies Métaboliques et Nutrition, Hôtel Dieu, Nantes, France Received 25 April 2000; received in revised form 22 September 2000; accepted 19 October 2000 Abstract The effect of a dietary fish oil supplementation on metabolism of HDL was studied in type II diabetes mellitus. Endogenous labeling of HDL-apo AI was performed using a 14 h primed infusion of D3-leucine in five diabetic patients before and 2 months after treatment with maxepa. Isotopic enrichment curves were analyzed using a monoexponential function. After treatment, plasma cholesterol level remained unchanged ( vs mg/dl, NS), whereas plasma triglycerides were decreased ( vs mg/dl, P=0.06). Plasma apo AI was similar under maxepa ( vs mg/dl, NS), and HDL-cholesterol and HDL-triglycerides were also not markedly changed ( vs mg/dl, and vs mg/dl, NS). HDL-apo AI fractional catabolic rate (FCR) and absolute production rate (APR) were significantly decreased after treatment with maxepa ( vs pool day, P 0.05, and vs mg/kg per day, P 0.05). These findings showed an effect of maxepa on kinetics of apolipoprotein AI in type II diabetes mellitus, probably linked to changes in plasma triglyceride level Elsevier Science Ireland Ltd. All rights reserved. Keywords: n-3 polyunsaturated acids; HDL; apo AI; Kinetic; Type II diabetes mellitus 1. Introduction Regular fish consumption has been correlated with a reduced mortality from coronary artery disease [1]. This event has been ascribed to the beneficial effect of two major long chain polyunsaturated omega-3 fatty acid ( 3-FA); eicosapentanoic acid (EPA, C20:5 3), and docosahexaenoic acid (DHA, C22:6 3). In patients with diabetes mellitus, plasma triglycerides were decreased and total cholesterol remain unchanged under 3-FA [2 6]. Furthermore, most intervention studies [2 4,7], but not all [5,6] showed no effect of 3-FA on the total HDL-cholesterol level. Discrepancies in lipid profile may be attributed to the characteristics of patients, the lack of control group, the amount of treatment administrated or the length of the study. * Corresponding author. Tel.: ; fax: address: mkrempf@sante.univ-nantes.fr (M. Krempf). Furthermore, THE effect of 3-FA on lipoprotein metabolism was partly established, yielding a reduced hepatic synthesis of VLDL-apo B100 [8]. However, their effects on HDL metabolism are not documented. We already demonstrated that the decrease of plasma apo AI level in type II diabetes was due to the increase of HDL catabolic rate, closely linked to plasma triglyceride level and HDL composition [9]. Besides, HDL clearance is related to plasma triglyceride concentration [9 11]. In this study, we have therefore tested the hypothesis that the reduction of plasma triglyceride level, achieved by dietary fish oil supplementation, may play a direct role in the kinetic aspects of HDL metabolism in type II diabetic patients. 2. Subjects, materials and methods Five type II diabetic patients were recruited, including four non menopausal women at the beginning of /01/$ - see front matter 2001 Elsevier Science Ireland Ltd. All rights reserved. PII: S (00)
2 132 R. Frénais et al. / Atherosclerosis 157 (2001) their menstrual cycle (Table 1). They were not taking any medication that could affect carbohydrate or lipid for at least one month before study, and were instructed by a dietician to eat a weight-maintenance diet (50% carbohydrates, 35% fat and 15% protein), for 1 month before the study. The experimental protocol was approved by the Ethical Committee of Nantes University Hospital, and informed consent was obtained before the study was started. Patients underwent a basal kinetic study the day before the beginning of the treatment. Then they received six capsules 3-FA per day with meals for 8 weeks (maxepa, Pierre Fabre Sante, Castres, France). Each capsule contained 1000 mg methyl ester fatty acids, providing 180 mg eicosapentaenoic acid (EPA, 20:5 3), 120 mg docosahexaenoic acid (DHA, 22:6 3) and 1.75 mg alpha tocopherol acetate. The second kinetic was carried out at the end of treatment period. The kinetic protocol was similar to that previously described [9]. Briefly, the endogenous labeling of apolipoprotein AI was performed by administration of a primed constant infusion of 10 mol/kg per h L- [5,5,5-2 H 3 ]-leucine (Cambridge Isotope Laboratories, Andover, MA, USA) for 14 h. All the subjects fasted overnight before the study, and remained fasting during the entire protocol. Venous blood samples were withdrawn in EDTA tubes at baseline and at regular times until the end of the infusion. VLDL were isolated by a sequential ultracentrifugation (Himac CP70, Hitachi). HDL were then isolated by a density gradient ultracentrifugation (Centrikon T 2060, Kontron Instruments). Plasma and HDL cholesterol and triglyceride levels were measured using enzymatic kits (Boehringer Mannheim GmbH, Germany). Plasma apo AI concentration was measured by immunonephelometry (Behring, Rueil Malmaison, France). The apo AI pool size was calculated by multiplying the mean plasma apo AI concentration by , assuming a plasma volume of % of body weight according to age, gender and body weight of each study subject. HDL-apo AI and VLDL-apo B100 were isolated by SDS-PAGE and were hydrolysed with HCl (Sigma, St Quentin Fallavier, France). Hydrolysates were purified by cation exchange chromatography. Leucine was derivatized and isotopic ratios were analyzed by electron-impact gas chromatography-mass spectrometry [9]. Calculations of apo AI kinetic parameters were based on the tracer-to-tracee mass ratio. We applied a one-compartment model to HDL-apo AI and VLDL-apo B100 enrichment curves (SAAM II, Resource Facility for Kinetic Analysis, SAAM Institute, Seattle, WA). The plateau of VLDL-apo B100 tracer-to-tracee ratio was used as precursor pool enrichment, assuming that apo B100 and the majority of apo AI are synthesized by the liver. We estimated k the fractional catabolic rate (FCR, per day) and the absolute production rate (APR, mg/kg per day). APR was the product of FCR multiplied by apo AI pool size in HDL. We used the non-parametric Wilcoxon s signed ranktest to determine significant differences before and after 3-FA treatment (two-tailed). Furthermore, maxepa being considered as an hypotriglyceridemic treatment, we reported a one-tailed P value for plasma triglyceride levels. 3. Results Treatment with maxepa did not lead to significant variations of body mass index ( 1%), glycated haemoglobin level ( 4%), fasting blood glucose level ( 6%) or insulinemia ( 16%) (Table 1). Whereas 3-FA acids did not change total plasma cholesterol level ( 1%), plasma triglyceride level was markedly decreased ( 23%, P=0.06). The 3-FA treatment did not significantly change HDL composition, despite a trend to a higher HDL-cholesterol level ( +11%), and a decreased HDL-triglycerides level ( 20%). Apo AI level was also similar (+4%) (Table 1). As previously reported [9], a plateau of tracer-totracee ratio was observed for VLDL-apo B100 but not for apo AI-HDL, meaning a slow synthetic rate for this apolipoprotein (data not shown). Mean HDL-apo AI fractional catabolic rate (FCR) and absolute production rate (APR) were significantly decreased after treatment with maxepa ( vs pool per day, P 0.05, and vs mg/kg per day, P 0.05) (Table 1). 4. Discussion We have studied the effect of reduction of plasma triglyceride level, achieved by a dietary fish oil supplementation, on the kinetic aspects of HDL metabolism in type II diabetes. After 2 months of treatment, patients showed a marked reduction of plasma triglyceride concentration, whereas, plasma apoa1 and HDLcholesterol remained unchanged, as already reported [2 5]. Both the clearance and production rates of HDL-apo AI decreased significantly after treatment in all the patients. Although in the range of inclusion criteria (type II diabetes mellitus, plasma TG level g/l and HbA1c 12%), the small-sized study population was to some extent heterogeneous and this could constitute a limitation of the study. Patients also showed heterogeneity of response to the treatment regarding HDL components, probably explaining the lack of significant difference with treatment. We have applied a one-com-
3 Table 1 Clinical characteristics, plasma and HDL cholesterol and triglycerides levels, and HDL-apo AI kinetic parameters in type II diabetic patients before (base) and after (post) dietary fish oil supplementation a Subject Age (years) BMI HbA1c (%) Insulin Glucose Plasma CH Plasma TG HDL-CH HDL-TG Apo AI FCR (pool APR (kg/m 2 ) (mu/l) (mmol/l) (mg/dl) (mg/dl) (mg/dl) (mg/dl) (mg/dl) per day) (mg/kg per day) c1 Base Post c2 Base ND Post ND c3 Base Post c4 Base Post c5 Base Post Mean base S.D. (13) (2.7) (2.6) (6.3) (2.5) (30.7) (32.2) (10.0) (10.4) (25.4) Mean post b c 12.1 c S.D. (2.5) (1.8) (6.6) (3.0) (41.9) (67.9) (10.0) (9.8) (25.6) a CH, cholesterol; TG, triglyceride; FCR, fractional catabolic rate; APR, absolute production rate. b P=0.06. c P 0.05, post versus base. R. Frénais et al. / Atherosclerosis 157 (2001)
4 134 R. Frénais et al. / Atherosclerosis 157 (2001) partment to our enrichment data, which appears the most relevant under our study conditions (constant infusion) compared with munch complex model, and allows the study of apo AI overall catabolism. The lack of change in plasma apo AI level after fish oil supplementation, already reported [2,7], was in agreement with both decrease of production and catabolic rates of apoa1-hdl. The benefic effect of MaxEPA is validated since the production of HDL-apoA1 was similar to control value ( mg/kg per day) we have previously reported [9]. However, the decrease of HDL-apo AI clearance rate, although significant, was not strong enough to reach normal values ( pool per day). This could be an explanation of the low plasma apo AI level observed at the end of the study. But these values at the basal state were in agreement with previous studies on HDL kinetics, underlying the accuracy of our method. A decrease in both HDL-apo AI FCR and APR was observed in every study subjects, indicating that 3 fatty acids had an impact on HDL metabolic. HDL production was adapted to the increase of catabolism before and after fish oil supplementation. This is however not the case for all patients with glucose impaired tolerance (IGT) or type II diabetes mellitus [9,12], who showed no change in HDL absolute production rate. This would suggest that HDL production could depend on several genetic and environmental factors, which may finally control plasma apo AI concentration. We already reported that the FCR of HDL increased in type II diabetes, and related to plasma and HDLtriglycerides levels [9]. The present study was therefore designed to evaluate whether plasma triglycerides directly or secondarily via HDL-triglyceride level could act upon HDL clearance rate. A reduction of plasma triglyceride level, achieved by means of 3-FA, may induce a change in HDL composition, and particularly a decrease of HDL-triglyceride level. Several studies have indicated that HDL catabolism was related to HDL-triglyceride concentration or HL activity [13,14]. Thus, a reduction may be associated with a decrease of HDL clearance. However, this probably does not occur in this study since maxepa did not induce a clear-cut reduction of HDL-triglycerides, which was not consequently significantly correlated with HDL-apo AI catabolism (data not shown). This lack of change in HDL composition is in agreement with the unaffected HL activity and the increased LPL activity [7], as well as the decrease of VLDL production [8] after fish oil supplementation. In contrast, a lowered plasma triglyceride level, achieved by means of 3-FA, induces a decrease of HDL clearance rate. Therefore, these results suggest that plasma triglyceride level per se may play a role in the control of HDL metabolism. Nevertheless, definite conclusions are precluded by the small number of patients studied. Then, maxepa induces changes in HDL catabolism and this could be added to the beneficial cardiovascular effect of this treatment. These current kinetic data, even observed on a small-sized study group, may provide new insights about the mechanisms of action of fish oil, which remain open to further investigations. Acknowledgements We thank I. Grit, C. Le Valegant, and P. Maugère for their excellent technical assistance and D. Darmaun for his review and advice. This study was supported by grants from the department of Clinical Research of Nantes Hospital and from Pierre Fabre Sante Laboratories. References [1] Kromhout D, Bosscheiter EB, de Lezenne Coulander C. The inverse relation between fish consumption and 20-year mortality from coronary heart disease. New Engl J Med 1985;312: [2] Schectman G, Kaul S, Kissebah H. Effect of fish oil concentrate on lipoprotein composition in NIDDM. Diabetes 1988;37: [3] Goh YK, Jumpsen MA, Ryan EA, Clandinin MT. Effects of w-3 fatty acids on plasma lipids, cholesterol and lipoproteins fatty acid content in NIDDM patients. Diabetologia 1997;40: [4] Morgan WA, Raskin P, Rosenstock J. A comparison of fish oil or corn oil supplements in hyperlipidemic subjects with NIDDM. Diabetes Care 1995;18:83 6. [5] Dunstan DW, Mori TA, Puddey IB, Burke V, Morton AR, Stanton KG. The independent and combined effects of aerobic exercise and dietary fish intake on serum lipids and glycemic control in NIDDM: a randomized controlled study. Diabetes Care 1998;20: [6] Holub BJ, Bakker DJ, Skeaff CM. Alterations in molecular species of cholesterol esters formed via lecithin-cholesterol acyltransferase in human subjects consuming fish oil. Atherosclerosis 1987;66:11 8. [7] Kasim SE, Stern B, Khilnani S, McLin P, Baciorowski S, Jen KLC. Effects of w 3 fish oil on lipid metabolism, glycemic control, and blood pressure in type II diabetic patients. J Clin Endocrinol Metab 1988;67:1 5. [8] Fisher WR, Zech LA, Stacpoole PW. Apolipoprotein B metabolism in hypertriglyceridemic diabetic patients administered either a fish oil- or vegetable oil-enriched diet. J Lipid Res 1998;39: [9] Frénais R, Ouguerram K, Maugeais C, et al. High density lipoprotein apolipoprotein AI kinetics in NIDDM: a stable isotope study. Diabetologia 1997;40: [10] Brinton EA, Eisenberg S, Breslow JL. Increased apo AI and apo AII fractional catabolic rate in patients with low high density lipoprotein-cholesterol levels with or without hypertriglyceridemia. J Clin Invest 1991;87: [11] Nikkilä EA, Taskinen MR, Sane T. Plasma high density lipoprotein concentration and subfraction in relation to triglyceride metabolism. Am Heart J 1987;113: [12] Pietzch J, Julius U, Nitzsche S, Hanefeld M. In vivo evidence for increased apolipoprotein A-I catabolism in subjects with impaired glucose tolerance. Diabetes 1998;47:
5 R. Frénais et al. / Atherosclerosis 157 (2001) [13] Saku K, Gartside PS, Hynd BA, Mendoza SG, Kashyap ML. Apolipoprotein AI and AII metabolism in patients with primary high density lipoprotein deficiency associated with familial hypertriglyceridemia. Metabolism 1985;34: [14] Brinton EA, Eisenberg S, Breslow JL. Human HDL cholesterol levels are determined by apo AI fractional catabolic rate, which correlates inversely with estimates of HDL particle size. Arterioscler Thromb 1994;14:
Fish Oils and Diabetes
Fish Oils and Diabetes Summaries of the latest research concerning fish oils and diabetes Fish oils benefit women with diabetes BOSTON, MASSACHUSETTS. Several studies have found a clear inverse association
More informationAndré J. Tremblay, 1 Benoît Lamarche, 1 Jean-Charles Hogue, 1 and Patrick Couture 1,2. 1. Introduction. 2. Methods
Diabetes Research Volume 2016, Article ID 2909210, 5 pages http://dx.doi.org/10.1155/2016/2909210 Clinical Study n-3 Polyunsaturated Fatty Acid Supplementation Has No Effect on Postprandial Triglyceride-Rich
More informationHigh density lipoprotein metabolism
High density lipoprotein metabolism Lipoprotein classes and atherosclerosis Chylomicrons, VLDL, and their catabolic remnants Pro-atherogenic LDL HDL Anti-atherogenic Plasma lipid transport Liver VLDL FC
More informationChapter (5) Etiology of Low HDL- Cholesterol
Chapter (5) Etiology of Low HDL- Cholesterol The aim of this chapter is to summarize the different etiological factors mainly the role of life-style and different disease conditions contributing to the
More informationDick C Chan, Gerald F Watts, Minh N Nguyen, and P Hugh R Barrett
Factorial study of the effect of n 3 fatty acid supplementation and atorvastatin on the kinetics of HDL apolipoproteins A-I and A-II in men with abdominal obesity 1 3 Dick C Chan, Gerald F Watts, Minh
More informationEffect of a high-carbohydrate vs a high cis-monounsaturated fat diet on lipid and lipoproteins in individuals with and without type 2 diabetes B
Nutrition Research 24 (2004) 969 979 www.elsevier.com/locate/nutres Effect of a high-carbohydrate vs a high cis-monounsaturated fat diet on lipid and lipoproteins in individuals with and without type 2
More informationHypertriglyceridemia: Why, When, and How to Treat. Gregory Cohn, MD, FNLA, FASPC
Hypertriglyceridemia: Why, When, and How to Treat Gregory Cohn, MD, FNLA, FASPC DISCLOSURES Consultant to Akcea Therapeutics (in the past 12 months). OUTLINE I. Lipoproteins II. Non-HDL-C III. Causes and
More informationFacts on Fats. Ronald P. Mensink
Facts on Fats Ronald P. Mensink Department of Human Biology NUTRIM, School for Nutrition, Toxicology and Metabolism Maastricht University Maastricht The Netherlands Outline of the Presentation Saturated
More informationFuture directions for nutritional and therapeutic research in omega-3 3 lipids
Future directions for nutritional and therapeutic research in omega-3 3 lipids Philip Calder Professor of Nutritional Immunology University of Southampton Aim To review dietary sources and intakes of long
More informationLipoproteins Metabolism
Lipoproteins Metabolism LEARNING OBJECTIVES By the end of this Lecture, the student should be able to describe: What are Lipoproteins? Describe Lipoprotein Particles. Composition of Lipoproteins. The chemical
More informationReplacement Of Partially Hydrogenated Soybean Oil By Palm Oil In Margarine Without Unfavorable Effects On Serum Lipoproteins
Replacement Of Partially Hydrogenated Soybean Oil By Palm Oil In Margarine Without Unfavorable Effects On Serum Lipoproteins Muller H, Jordal O, et al. (998) Replacement of partially hydrogenated soybean
More informationANTIHYPERLIPIDEMIA. Darmawan,dr.,M.Kes,Sp.PD
ANTIHYPERLIPIDEMIA Darmawan,dr.,M.Kes,Sp.PD Plasma lipids consist mostly of lipoproteins Spherical complexes of lipids and specific proteins (apolipoproteins). The clinically important lipoproteins, listed
More informationThe Effects of Glibenclamide on Serum Lipids and Lipoproteins in Type II Non-Insulin Dependent Diabetes Mellitus
The Effects of Glibenclamide on Serum Lipids and Lipoproteins in Type II Non-Insulin Dependent Diabetes Mellitus Pages with reference to book, From 89 To 92 Muhammad Azhar Mughal,Kausar Aamir,Mehar Ali
More informationAntihyperlipidemic Drugs
Antihyperlipidemic Drugs Hyperlipidemias. Hyperlipoproteinemias. Hyperlipemia. Hypercholestrolemia. Direct relationship with acute pancreatitis and atherosclerosis Structure Lipoprotein Particles Types
More informationThe health benefits of shellfish: What should we be promoting? Professor Bruce Griffin Nutrition Division Faculty of Health & Medical Sciences
The health benefits of shellfish: What should we be promoting? Professor Bruce Griffin Nutrition Division Faculty of Health & Medical Sciences What should we be promoting? Define health benefits in terms
More information1Why lipids cannot be transported in blood alone? 2How we transport Fatty acids and steroid hormones?
1Why lipids cannot be transported in blood alone? 2How we transport Fatty acids and steroid hormones? 3How are dietary lipids transported? 4How lipids synthesized in the liver are transported? 5 Lipoprotien
More informationSUPPLEMENTAL FILE MATERIALS AND METHODS. Effects of extended-release nicotinic acid on apolipoprotein (a) kinetics in. hypertriglyceridemic patients
SUPPLEMENTAL FILE MATERIALS AND METHODS Effects of extended-release nicotinic acid on apolipoprotein (a) kinetics in hypertriglyceridemic patients 1 1 1 Mikaël Croyal, Khadija Ouguerram, Maxime Passard,
More informationThe effect of plant sterols and different low doses of omega-3 fatty acids from fish oil on lipoprotein subclasses
The effect of plant sterols and different low doses of omega-3 fatty acids from fish oil on lipoprotein subclasses 18 June 2015 Doris Jacobs Unilever R&D Vlaardingen Background Elevated low-density lipoprotein-cholesterol
More informationDetermination of kinetic parameters of apolipoprotein B metabolism using amino acids labeled with stable isotopes
Determination of kinetic parameters of apolipoprotein B metabolism using amino acids labeled with stable isotopes Klaus G. Parhofer, P. Hugh R. Barrett,t Dennis M. Bier,* and Gustav Schonfeld Division
More informationZuhier Awan, MD, PhD, FRCPC
Metabolism, Atherogenic Properties and Agents to Reduce Triglyceride-Rich Lipoproteins (TRL) The Fifth IAS-OSLA Course on Lipid Metabolism and Cardiovascular Risk Muscat, Oman, February 8-11, 2019 Zuhier
More information13/09/2012. Dietary fatty acids. Triglyceride. Phospholipids:
CARDIOVASCULAR DISEASES (CVD) and NUTRITION Major cause of morbidity & mortality in Canada & other developed countries e.g., majority of approved health claims on food labels relate to lowering CVD Relation
More informationBehind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL
Behind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL Sung-Joon Lee, PhD Division of Food Science Institute of Biomedical Science and Safety Korea University Composition of Lipoproteins:
More information2.5% of all deaths globally each year. 7th leading cause of death by % of people with diabetes live in low and middle income countries
Lipid Disorders in Diabetes (Diabetic Dyslipidemia) Khosrow Adeli PhD, FCACB, DABCC Head and Professor, Clinical Biochemistry, The Hospital for Sick Children, University it of Toronto Diabetes A Global
More informationANSC/NUTR 618 LIPIDS & LIPID METABOLISM Lipoprotein Metabolism
ANSC/NUTR 618 LIPIDS & LIPID METABOLISM Lipoprotein Metabolism I. Chylomicrons (exogenous pathway) A. 83% triacylglycerol, 2% protein, 8% cholesterol plus cholesterol esters, 7% phospholipid (esp. phosphatidylcholine)
More informationHypertriglyceridemia. Ara Metjian, M.D. Resident s Report 20 December 2002
Hypertriglyceridemia Ara Metjian, M.D. Resident s Report 20 December 2002 Review of Lipids Chylomicrons (CM): Dietary lipids absorbed through the GI tract are assembled intracellularly into CM. Very Low
More informationEicosapentaenoic Acid and Docosahexaenoic Acid: Are They Different?
Eicosapentaenoic Acid and Docosahexaenoic Acid: Are They Different? Trevor A Mori, Ph.D., Professor, School of Medicine and Pharmacology, Royal Perth Hospital Unit, University of Western Australia, Perth,
More informationBringing metabolic profiling into clinical practice. Linda Mustelin, MD, PhD, MPH Senior Medical Scientist Nightingale Health
Bringing metabolic profiling into clinical practice Linda Mustelin, MD, PhD, MPH Senior Medical Scientist Nightingale Health Nightingale Health Ltd. Finnish biotech company specialized in comprehensive
More informationThe art of tracing dietary fat in humans. Leanne Hodson
The art of tracing dietary fat in humans Leanne Hodson Dietary fat Other lipoproteins: IDL, LDL, HDL Hodson and Fielding linical Lipidology (2010) Relationship between blood & dietary fatty acids Typically:
More informationLipids Board Review. Ira Goldberg, MD New York University School of Medicine. Which of the following is the best initial therapy choice?
Lipids Board Review Ira Goldberg, MD New York University School of Medicine 1. A 22 year old male college student is referred for severe hypertriglyceridemia ( 1500 mg/dl [ 17.0 mmol/l]). He has a history
More informationCell Surface Expression of LDL Receptor Is Decreased in Type 2 Diabetic Patients and Is Normalized by Insulin Therapy
Pathophysiology/Complications O R I G I N A L A R T I C L E Cell Surface Expression of LDL Receptor Is Decreased in Type 2 Diabetic Patients and Is Normalized by Insulin Therapy LAURENCE DUVILLARD, MD,
More informationPattern of lipid biomarkers and risk of cardiovascular disease
Pattern of lipid biomarkers and risk of cardiovascular disease Robert Clarke Clinical Trial Service Unit University of Oxford 9 January 2017 Biomarkers for dietary fats Blood lipids (LDL, HDL, triglycerides,
More informationKeywords: coronary heart disease; hypertriglyceridaemia; polyunsaturated fat; statin treatment
544 University Department of Medicine, Manchester Royal Infirmary, Oxford Road, Manchester M13 9WL, UK P N Durrington D Bhatnagar M I Mackness J Morgan K Julier M A Khan M France Correspondence to: Professor
More informationOmega-3 Fatty Acids. Alison L. Bailey MD, FACC Erlanger Heart and Lung Institute/University of Tennessee COM
Omega-3 Fatty Acids Alison L. Bailey MD, FACC Erlanger Heart and Lung Institute/University of Tennessee COM Chattanooga @a_l_bailey Disclosures None Objectives Describe omega-3 fatty acids Review the historic
More informationSkeletal muscle metabolism was studied by measuring arterio-venous concentration differences
Supplemental Data Dual stable-isotope experiment Skeletal muscle metabolism was studied by measuring arterio-venous concentration differences across the forearm, adjusted for forearm blood flow (FBF) (1).
More informationGender: M Chart No: Fasting: Yes. Boston Heart HDL Map TM Test 1 ApoA-I (mg/dl) levels in HDL particles. α Range > <14 mg/dl. α-2 50.
Pro vider: Ordering Provider 123 Main Street Anytown, ST 12345 Account No: DOB: 00/00/1950 Framingham Risk Score: Patient Info: FAMILY HIST CVD Lipid, Lipoprotein and Apolipoprotein Tests Total Cholesterol
More informationDownloaded from ismj.bpums.ac.ir at 21: on Friday March 22nd 2019
(1384 ) 8-14 1 4 3 1 2 1* 2 3 1 4. 6 3 : (6 ) (3 ). LDL HDL. :. 50mg/kg.. HDL LDL. 6/8 40/7 : LDL. HDL :. 84/6/15 : 84/6/1 : : 83/12/1 : shariatik @ Yahoo.com : 5234003 : - * 9 /.(9 8). (ω3) (15) LDL (14)
More informationDesign and analysis of lipoprotein tracer kinetic studies in humans
Design and analysis of lipoprotein tracer kinetic studies in humans P Hugh R Barrett, Dick C Chan and Gerald F Watts Metabolic Research Centre, School of Medicine and Pharmacology, University of Western
More informationName of Policy: Measurement of Long-Chain Omega-3 Fatty Acids in Red Blood Cell Membranes as a Cardiac Risk Factor
Name of Policy: Measurement of Long-Chain Omega-3 Fatty Acids in Red Blood Cell Membranes as a Cardiac Risk Factor Policy #: 239 Latest Review Date: July 2010 Category: Laboratory Policy Grade: Active
More informationJMSCR Vol 05 Issue 05 Page May 2017
www.jmscr.igmpublication.org Impact Factor 5.84 Index Copernicus Value: 83.27 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v5i5.193 Lipid Profile as Early Predictor of Complication
More informationThere are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk?
There are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk? Michael Davidson M.D. FACC, Diplomate of the American Board of Lipidology Professor,
More informationInteractions of exercise and diet in health prevention
Interactions of exercise and diet in health prevention Dr Jason Gill Institute of Cardiovascular and Medical Sciences University of Glasgow Physical activity and health outcomes does one size fit all?
More informationThe New Gold Standard for Lipoprotein Analysis. Advanced Testing for Cardiovascular Risk
The New Gold Standard for Lipoprotein Analysis Advanced Testing for Cardiovascular Risk Evolution of Lipoprotein Testing The Lipid Panel Total Cholesterol = VLDL + LDL + HDL Evolution of Lipoprotein Testing
More informationFish Oils and Stroke/Blood Coagulation
Fish Oils and Stroke/Blood Coagulation Summaries of the latest research concerning fish oils and stroke and blood coagulation Review supports benefits of omega-3 fatty acids for prevention of heart disease
More informationUnit IV Problem 3 Biochemistry: Cholesterol Metabolism and Lipoproteins
Unit IV Problem 3 Biochemistry: Cholesterol Metabolism and Lipoproteins - Cholesterol: It is a sterol which is found in all eukaryotic cells and contains an oxygen (as a hydroxyl group OH) on Carbon number
More informationDownloaded from armaghanj.yums.ac.ir at 12: on Friday August 17th 2018
: / :.... :. ( ) ( )... SPSS. FPII. :..( p= /) :. * ** *** **** ***** ****** ******* ******* * ** *** **** ***** ****** ******* / / : // : : jalalimahmoud@hotmail.com : : . /.. ). (. /..( )...... B.. (
More informationComprehensive Treatment for Dyslipidemias. Eric L. Pacini, MD Oregon Cardiology 2012 Cardiovascular Symposium
Comprehensive Treatment for Dyslipidemias Eric L. Pacini, MD Oregon Cardiology 2012 Cardiovascular Symposium Primary Prevention 41 y/o healthy male No Medications Normal BP, Glucose and BMI Social History:
More informationGlossary For TheFatNurse s For All Ages Series Apolipoprotein B (APOB or ApoB) are the primary apolipoproteins of chylomicrons and low-density lipoproteins (LDL - known commonly by the misnomer "bad cholesterol"
More informationSaturated fat- how long can you go/how low should you go?
Saturated fat- how long can you go/how low should you go? Peter Clifton Baker IDI Heart and Diabetes Institute Page 1: Baker IDI Page 2: Baker IDI Page 3: Baker IDI FIGURE 1. Predicted changes ({Delta})
More informationLipid modification in type 2 diabetes: the role of LDL and HDL
REVIEW ARTICLE doi: 10.1111/j.1472-8206.2009.00739.x Lipid modification in type 2 diabetes: the role of LDL and HDL Bruno Vergès* Service d Endocrinologie, Diabétologie et Maladies Métaboliques, Hôpital
More informationMetabolism and Atherogenic Properties of LDL
Metabolism and Atherogenic Properties of LDL Manfredi Rizzo, MD, PhD Associate Professor of Internal Medicine Faculty of Medicine, University of Palermo, Italy & Affiliate Associate Professor of Internal
More informationAssociation between skeletal muscle fat content and very-low density. lipoprotein-apolipoprotein B-100 transport in obesity: effect of weight loss
Association between skeletal muscle fat content and very-low density lipoprotein-apolipoprotein B-100 transport in obesity: effect of weight loss D.C. Chan, S.K. Gan, A.T.Y. Wong, P.H.R. Barrett, G.F.
More informationFig. S1. REGN1500 reduces plasma levels of cholesterol, TG and NEFA in WT and Ldlr -/- mice. (A) WT
Figure Legends for Supplementary Figures. Fig. S1. REGN15 reduces plasma levels of cholesterol, TG and NEF in WT and Ldlr -/- mice. () WT and Ldlr -/- mice were injected with control IgG or REGN15 (1 mg/kg)
More informationPlasma kinetics of apoc-iii and apoe in normolipidemic and hypertriglyceridemic subjects
Plasma kinetics of apoc-iii and apoe in normolipidemic and hypertriglyceridemic subjects Rami Batal,* Michel Tremblay,* P. Hugh R. Barrett, Hélène Jacques,* Alexandre Fredenrich,* Orval Mamer, Jean Davignon,*
More informationTHE PROBLEM OMEGA 3. pure
p2 THE PROBLEM Essential fatty acids (EFAs) are polyunsaturated fats that our bodies need but cannot produce. Therefore, they must be consumed through food or supplements. Omega 3 and Omega 6 are EFAs.
More informationHBA1C: PREDICTOR OF DYSLIPIDEMIA AND ATHEROGENICITY IN DIABETES MELLITUS
Original Article HBA1C: PREDICTOR OF DYSLIPIDEMIA AND ATHEROGENICITY IN DIABETES MELLITUS Chintamani Bodhe*, Deepali Jankar**, Tara Bhutada***, Milind Patwardhan****, Mrs Varsha Patwardhan***** ABSTRACT
More informationInvestigations on the mechanism of hypercholesterolemia observed in copper deficiency in rats
J. Biosci., Vol. 12, Number 2, June 1987, pp. 137 142. Printed in India. Investigations on the mechanism of hypercholesterolemia observed in copper deficiency in rats P. VALSALA and P. A. KURUP Department
More informationLipoprotein Particle Profile
Lipoprotein Particle Profile 50% of people at risk for HEART DISEASE are not identified by routine testing. Why is LPP Testing The Most Comprehensive Risk Assessment? u Provides much more accurate cardiovascular
More informationDietary Lipid Utilization by Haddock (Melanogrammus aeglefinus)
Dietary Lipid Utilization by Haddock (Melanogrammus aeglefinus) Santosh P. Lall & Dominic A. Nanton National Research Council of Canada Halifax, Canada vis, California ne 23, 2003 Body Components of Wild
More informationAAOCS 10 th Biennial Conference Barossa Valley, September Presenter: Petter-Arnt Hals MSc PhD Co-authors: Nils Hoem, Xiaoli Wang, Yong-Fu Xiao
Effects of a purified, omega-3 rich krill oil phospholipid on cardiovascular disease risk factors and fatty acid composition of erythrocyte membranes in non-human primates AAOCS 10 th Biennial Conference
More informationApproach to Dyslipidemia among diabetic patients
Approach to Dyslipidemia among diabetic patients Farzad Hadaegh, MD, Professor of Internal Medicine & Endocrinology Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences
More information298 Biomed Environ Sci, 2015; 28(4):
298 Biomed Environ Sci, 2015; 28(4): 298-302 Letter to the Editor Effects of Maternal Linseed Oil Supplementation on Metabolic Parameters in Cafeteria Diet-induced Obese Rats * BENAISSA Nawel 1, MERZOUK
More informationCurrently, the most effective established insulinreplacement
The Effect of Systemic Versus Portal Insulin Delivery in Pancreas Transplantation on Insulin Action and VLDL Metabolism André Carpentier, 1 Bruce W. Patterson, 4 Kristine D. Uffelman, 1 Adria Giacca, 1,2
More informationThe legally binding text is the original French version
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION December 5, 2007 MAXEPA 1g, capsule Box of 60 (CIP: 329 763-8) Applicant: PIERRE FABRE MEDICAMENT Natural fish oil
More informationLipid profile in Diabetes Mellitus
International Journal of Biotechnology and Biochemistry ISSN 0973-2691 Volume 13, Number 2 (2017) pp. 123-131 Research India Publications http://www.ripublication.com Lipid profile in Diabetes Mellitus
More information: Overview of EFA metabolism
Figure 1 gives an overview of the metabolic fate of the EFAs when consumed in the diet. The n-6 and n-3 PUFAs when consumed in the form of dietary triglyceride from various food sources undergoes digestion
More informationNutrition Basics. Chapter McGraw-Hill Higher Education. All rights reserved.
Nutrition Basics Chapter 12 1 The Body s Nutritional Requirements Essential nutrients The Six Essential Nutrients: Proteins, Fats, Carbohydrates, Vitamins, Minerals, Water Defined as : Nutrients one must
More informationDYSLIPIDAEMIC PATTERN OF PATIENTS WITH TYPE 2 DIABETES MELLITUS. Eid Mohamed, Mafauzy Mohamed*, Faridah Abdul Rashid
Malaysian Journal of Medical Sciences, Vol. 11, No. 1, January 2004 (44-51) ORIGINAL ARTICLE DYSLIPIDAEMIC PATTERN OF PATIENTS WITH TYPE 2 DIABETES MELLITUS Eid Mohamed, Mafauzy Mohamed*, Faridah Abdul
More informationLipid/Lipoprotein Structure and Metabolism (Overview)
Lipid/Lipoprotein Structure and Metabolism (Overview) Philip Barter President, International Atherosclerosis Society Centre for Vascular Research University of New South Wales Sydney, Australia Disclosures
More informationThe mechanisms regulating the synthesis and secretion of
Human Apolipoprotein (Apo) B-48 and ApoB-100 Kinetics With Stable Isotopes Francine K. Welty, Alice H. Lichtenstein, P. Hugh R. Barrett, Gregory G. Dolnikowski, Ernst J. Schaefer Abstract The kinetics
More informationThe Role of Apolipoprotein CIII in Coronary Artery Disease. Disclosures
Miami Cardiac & Vascular Institute Cardiovascular Disease Prevention 15th Annual Symposium February 16, 2017 Nobu Eden Roc Hotel, Miami Beach, Florida. The Role of Apolipoprotein CIII in Coronary Artery
More informationSTUDY QUESTIONS, Chapter 5: The Lipids: Fats, Oils, Phospholipids and Sterols
STUDY QUESTIONS, Chapter 5: The Lipids: Fats, Oils, Phospholipids and Sterols To answer the next questions, read the introductory paragraphs, Introducing the Lipids and A Close Look at Lipids in Ch. 5.
More informationNutritional Recommendations for the Diabetes Managements
In the name of God Nutritional for the Diabetes Managements Zohreh Mazloom. PhD Shiraz University of Medical Sciences School of Nutrition and Food Sciences Department of Clinical Nutrition OVERVIEW Healthful
More informationDisclosures. Background 1 What is Known MENOPAUSE, ESTROGENS, AND LIPOPROTEIN PARTICLES. Background 2 What is Not Known 10/2/2017
Disclosures MENOPAUSE, ESTROGENS, AND LIPOPROTEIN PARTICLES Grants: NIH, Quest Diagnostics Consultant: Quest Diagnostics Merck Global Atherosclerosis Advisory Board Ronald M. Krauss, Children s Hospital
More informationLIPIDS OF PHYSIOLOGICAL SIGNIFICANCE
LIPIDS OF PHYSIOLOGICAL SIGNIFICANCE Original slides. Important. 436 Notes 438 notes Extra information رابط التعديل: https://docs.google.com/document/d/1wvdec1atp7j- ZKWOUSukSLsEcosjZ0AqV4z2VcH2TA0/edit?usp=sharing
More informationEssential Fatty Acids Essential for Good Health SIE
Page 1 of 6 Essential Fatty Acids Essential for Good Health SIE By Yousry Naguib, PhD Essential fatty acids (EFAs) must be obtained through the diet and cannot be synthesized by the human body. EFAs are
More informationAcetyl CoA HMG CoA Mevalonate (C6) Dimethylallyl Pyrophosphate isopentenyl Pyrophosphate (C5) Geranyl Pyrophosphate (C10) FarnesylPyrophosphate (C15) Squalene (C30) Lanosterol (C30) 7 Dehydrocholesterol
More informationEffect of TAK-085 on Low-density Lipoprotein Particle Size in Patients with Hypertriglyceridemia: A Double-blind Randomized Clinical Study
ORIGINAL RESEARCH ARTICLE Effect of TAK-085 on Low-density Lipoprotein Particle Size in Patients with Hypertriglyceridemia: A Double-blind Randomized Clinical Study Ichiro Tatsuno, 1 Kentarou Kudou 2 &
More informationRELATIONSHIP BETWEEN DIETARY CARBOHYDRATES AND FATS IN THEIR INFLUENCE ON SERUM LIPID CONCENTRATIONS
Clinical Science (1972) 43,265-214. RELATIONSHIP BETWEEN DIETARY CARBOHYDRATES AND FATS IN THEIR INFLUENCE ON SERUM LIPID CONCENTRATIONS I. MACDONALD Department of Physiology, Guy s Hospital Medical School,
More informationFATS The Facts. compiled by the Nestlé Research Center
FATS The Facts compiled by the Nestlé Research Center Dietary fats are a public health concern Dietary fats are necessary for ensuring optimal health. Recent dietary guidelines focus on fat quality and
More informationMarshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona,
Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona, Jamaica At the end of this presentation the participant
More informationCardiovascular Complications of Diabetes
VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary
More informationMass kinetics of apolipoprotein A-I in interstitial fluid after administration of intravenous apolipoprotein A-I/lecithin discs in humans
Mass kinetics of apolipoprotein A-I in interstitial fluid after administration of intravenous apolipoprotein A-I/lecithin discs in humans Roman Hovorka,* M. Nazeem Nanjee, C. Justin Cooke, Irina P. Miller,
More informationGlossary For TheFatNurse s For All Ages Series Adipocytes, also known as lipocytes and fat cells, are the cells that primarily compose adipose tissue, specialized in storing energy as fat. Apolipoprotein
More informationSoo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital
Soo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital 1. Importance of Lowering LDL-Cholesterol in Diabetes Patients & Lipid Guidelines Prevalence of dyslipidemia in Korea Prevalence
More informationPathophysiology of Lipid Disorders
Pathophysiology of Lipid Disorders Henry Ginsberg, M.D. Division of Preventive Medicine and Nutrition CHD in the United States CHD is the single largest killer of men and women 12 million have history
More informationMetabolic defects underlying dyslipidemia in abdominal obesity
Metabolic defects underlying dyslipidemia in abdominal obesity Professor Marja-Riitta Taskinen Department of Medicine, Division of Cardiology Helsinki University Hospital, Finland Disclosures: Honorariums/
More informationLipid profile in Diabetes Mellitus
Original Research Shankarprasad DS 1,*, Shivanand Gundalli 2, Mahantesh B 3, SV Kashinakunti 4, Sunitha P 5 1,4 Professor, 3 Postgradute student, 5 Associate Professor, Department of Biochemistry, 2 Assistant
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/21953 holds various files of this Leiden University dissertation. Author: Schalkwijk, Daniël Bernardus van Title: Computational modeling of lipoprotein
More informationResponses of blood lipids to aerobic and resistance type of exercise
Responses of blood lipids to aerobic and resistance type of exercise Labros Sidossis, Ph.D. Laboratory of Nutrition and Clinical Dietetics Harokopio University of Athens, Greece Triacylglycerol structure
More informationSeparation of HDL Particles by Immunoprecipitation
Sun Diagnostics, LLC Separation of HDL Particles by Immunoprecipitation Rae-Anne Nguyen and John H. Contois 13 Introduction We all know that HDL cholesterol concentration is inversely associated with coronary
More informationNutrition & Wellness for Life 2012 Chapter 6: Fats: A Concentrated Energy Source
Tools: Printer 8.5 x 11 paper Scissors Directions: 1. Print 2. Fold paper in half vertically 3. Cut along dashed lines Copyright Goodheart-Willcox Co., Inc. All rights reserved. Tissue in which the body
More informationHeart Health and Fats
ww Heart Health and Fats By Marie Spano, M.S., R.D., C.S.C.S., Contributing Editor Dietary-fat recommendations for heart health are more specific now then ever, breaking down different types of polyunsaturated
More informationLow-fat dietary pattern and lipoprotein risk factors: the Women s Health Initiative Dietary Modification Trial 1 4
See corresponding editorial on page 829. Low-fat dietary pattern and lipoprotein risk factors: the Women s Health Initiative Dietary Modification Trial 1 4 Barbara V Howard, J David Curb, Charles B Eaton,
More informationFructose in diabetes: Friend or Foe. Kim Chong Hwa MD,PhD Sejong general hospital, Division of Endocrinology & Metabolism
Fructose in diabetes: Friend or Foe Kim Chong Hwa MD,PhD Sejong general hospital, Division of Endocrinology & Metabolism Contents What is Fructose? Why is Fructose of Concern? Effects of Fructose on glycemic
More informationThe Role of LCPUFA in Obesity. M.Tom Clandinin. The Alberta Institute for Human Nutrition The University of Alberta Edmonton, Alberta, Canada
The Role of LCPUFA in Obesity by M.Tom Clandinin The Alberta Institute for Human Nutrition The University of Alberta Edmonton, Alberta, Canada How big is the Conceptual Problem? Some assumptions: 150lb
More informationOptimize Your Omega-3 Status Personalized Blood Test Reveals a Novel Cardiac Risk Factor
http://www.lef.org/ Life Extension Magazine May 2010 Optimize Your Omega-3 Status Personalized Blood Test Reveals a Novel Cardiac Risk Factor By Julius Goepp, MD Suppose you could assess with precision
More informationMaintain Cholesterol
Maintain Cholesterol What is Cholesterol? Cholesterol is a Lipid Molecule that has a waxy appearance and is found in every cell of the body and has some important natural functions. It is manufactured
More informationContributions from plasma NEFA, diet and de novo lipogenesis-derived fatty. acids to fasting VLDL-triglycerides
Contributions from plasma NEFA, diet and de novo lipogenesis-derived fatty acids to fasting VLDL-triglycerides via the delayed secretory pathway in humans Aruna Vedala 1, Wei Wang 1, Richard A. Neese 1,
More informationFISH. College of Applied Medical Sciences Department of Community Health Sciences Clinical Nutrition Functional Foods CHS 457 Level 9
College of Applied Medical Sciences Department of Community Health Sciences Clinical Nutrition Functional Foods CHS 457 Level 9 FISH Presented By: Nada Abdullah Al-Akeil Supervised By: Mrs.Madawi Al-Dhwayan
More informationAbdominal obesity, which is frequent in the general
Early Kinetic Abnormalities of ApoB-Containing Lipoproteins in Insulin-Resistant With Abdominal Obesity Frédéric Pont, Laurence Duvillard, Emmanuel Florentin, Philippe Gambert, Bruno Vergès Objective The
More information